Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right
Executive Summary
Cipla is planning an ambitious growth trajectory, aiming to propel its US business “towards a $1bn generic enterprise” and develop a strong specialty franchise focused on its traditional stronghold, the respiratory segment, and the CNS space.
You may also be interested in...
Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2
Early traction for its differentiated neurology and dermatology formulations in the US and signs of ebbing volatility in emerging markets bode well for Dr Reddy's Laboratories, amid a sharp decline in second quarter profits on a year-on-year basis. Investors also have their eyes firmly set on progress of the firm's key generic opportunities for Copaxone, Aloxi and Gleevec in the US.
JPM 2016: Cipla Shapes Respiratory Build-Up
Around a quarter of Cipla's top 50 R&D projects currently underway are in the respiratory segment and the Indian firm says it aims to launch its own differentiated respiratory and oncology pipeline in the US in the "near future."
Cipla Injects Scale With $550m US Buy
Cipla is acquiring the US-based firms InvaGen Pharmaceuticals and Exelan Pharmaceuticals for $550m, a deal which is expected to arm the India company with a ready basket of on-market generic drugs and attractive filings in addition to a manufacturing base as it ramps up in the US.